Rheologics Technologies, Inc. (PINKSHEETS: RTGI) (“Rheologics,” the “Company”), the leader in the study of blood viscosity and its relationship to cardiovascular and vascular diseases, announces the results of a study performed at the University of Chicago using the Rheolog™, the Company’s proprietary blood viscometer. The research demonstrated significantly higher blood viscosity in lupus patients with a history of heart attack or stroke over healthy controls and lupus patients with no history of cardiovascular events.
